S. 2140 · 118th Congress · Commerce

Patent Eligibility Restoration Act of 2023

Died in committee1.1k words Introduced Jun 22, 2023 · Latest action Jan 23, 2024

How far it has goneStopped at 2 of 6 · Died in committee
  1. IntroducedJun 22, 2023 Done
  2. CommitteeDied Jan 3, 2025 Stopped here
  3. Senate floorNot yet Not reached yet
  4. House floorNot yet Not reached yet
  5. Chambers agreeNot yet Not reached yet
  6. PresidentNot yet Not reached yet

What it does

This bill amends the law relating to patent subject matter eligibility to establish that only specified subject matter (e.g., a natural process wholly independent of human activity) is ineligible for patenting. (Currently, subject matter eligibility is determined by examining whether the claimed invention is directed to certain ineligible categories, and if so, whether there is an inventive concept. Subject matter eligibility is one of several requirements that an invention must satisfy in order to receive patent protection.)

Under this bill, an invention shall be considered to involve patent-ineligible subject matter only if it falls within specified categories, such as (1) a mathematical formula that is not part of a useful process, machine, manufacture, or composition; (2) a mental process that is performed solely in the human mind; or (3) an unmodified human gene as the gene exists in the human body.

Congressional Research Service · summary of “Introduced in Senate” version · Jun 22, 2023

Who lobbies on it

27 organizations · 130 filings · Q2 2023–Q4 2024

One square per quarter since introduction, oldest left. Filled = named it that quarter.

  1. Pharmaceutical Research and Manufacturers of America 7 of 7 quarters
    “H.R. 1717: Interagency Patent Coordination and Improvement Act of 2023 H.R. 4370: PREVAIL Act - Provisions related to the PTAB H.R. 4692: Increasing Prescription Drug Competition Act - Patent-related policy issues H.R. 5429: Medication Affordability and Patent Integrity Act H.R. 5475: Prohibiting Adversarial Patents…”

    Q4 2024 filing · $31.0M lobbying spend in 2024, all issues

  2. Microsoft Corporation 7 of 7 quarters
    “Software copyright and related policy issues. Software patents and related policy issues. S. 2220, Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act. S. 2934,SHOP SAFE Act. S. 2140, Patent Eligibility Restoration Act of 2023.”

    Q4 2024 filing · $9.4M lobbying spend in 2024, all issues

  3. Medtronic Inc 7 of 7 quarters
    “Issues related to intellectual property, including S. 2140, the Patent Eligibility Restoration Act of 2023 and S.2220 the Promoting and Respecting Economically Vital American Innovation Leadership Act”

    Q4 2024 filing · $4.3M lobbying spend in 2024, all issues

24 more organizations, every filingPROUpgrade

Organizations that named S. 2140 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. Source: Senate lobbying disclosures (LD-2) from lda.gov; quotes are word for word from the “specific lobbying issues” field.

Actions

3 actions · newest first
  1. Jan 23, 2024Committee on the Judiciary Subcommittee on Intellectual Property. Hearings held. With printed Hearing: S.Hrg. 118-460.
  2. Jun 22, 2023Read twice and referred to the Committee on the Judiciary.
  3. Jun 22, 2023Introduced in Senate